HUE032253T2 - Nitroxil donorok pulmonális hypertonia kezelésére - Google Patents

Nitroxil donorok pulmonális hypertonia kezelésére Download PDF

Info

Publication number
HUE032253T2
HUE032253T2 HUE10784416A HUE10784416A HUE032253T2 HU E032253 T2 HUE032253 T2 HU E032253T2 HU E10784416 A HUE10784416 A HU E10784416A HU E10784416 A HUE10784416 A HU E10784416A HU E032253 T2 HUE032253 T2 HU E032253T2
Authority
HU
Hungary
Prior art keywords
alkyl
substituted
iks
halo
amely amely
Prior art date
Application number
HUE10784416A
Other languages
English (en)
Inventor
Vincent J Kalish
Reza Mazhari
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of HUE032253T2 publication Critical patent/HUE032253T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (3)

  1. Xsab&amp;dabü lgésvp>m»k R 4 4 4 ^ i <*V N KVs v ' « ' s v v? ' 4 \ > >^ ' ^ ' '> s iïsrisbxaass &amp; slmas-l dooor halásos men?xyi*£g«s«k. adagolásà? e.uU'>*BÜ · am&amp;ysak. ms stAncâ' V4d, aboi a o&amp;uhíí donvr beptet 1 mrlns» u-gyuks
    vagy &amp;imk gyègyaxetéstmHeg «ifogsdhsté sósa, ahol: Rä H; R? H; li Rs è* R' fôggrKkmil y.: vas Âàw Mveifekb Wmc îi Mte, sMsssI&amp;ïi JP |«ls»s.<l.ig«8&amp;!^íáx|* |x-ihahalk*l jwtrcv sál, « :afes&amp; pf&amp;ïIsslMs-k. ;AI? wtowll Φί^Μ, ÂsæMÎ&amp; siMRüURmb hwomklosM, ÄÄ |:i«iö«l| »kitealno, c&amp;tetikmi v|Mö#kilB®kiäail, gbllpilaiRiÁs Mfsxylüöil |, A?. I igéxypom aaerim* îmrnül donor lelhaazsiálá:«;» dyanhbsa. ahogy aa as I. igänypmsban definiálva v&amp;n. ahoi s ha*á?os< «srmynég kisebb, skint fcÄlibelöl;· b gä%fiu$. '^s^< sim &amp;a îaS omber, 3v A*! I. igénypont ms Inti mtroxsl donor fÄsskssViasni eljárása, ahogy as \ vagy %,-4géoy:xv:i:ba} éebnkJva vao. abd &amp; vegyük; astravénásán, orálisan. vagy inhalálással vas adagolva 4,: Ás: I, agesÿfxxü sseríálí niooxsi ílöftöf felhasxoálásíra «lyibsbas, ahogy m I -3. igéxypontnk :bppiály|lÁbös ásRöitáiva vas, sM m piámmMm byperkxsSá pdmonÄ iilfe Ryprboip áppáís imíísksmksllfass pöte?PííálÁ::ky?ysypBÍ8s vagy bal OkíMI sgigbeppsgssg íaÁRA? bshkööllll Üfif^niá, «boka háíbldnb ssívhesssg^^jMIIi^.W hliMi |sÀë|êgpl®S#i4 vs s&amp;öi I’haJ bkläSi sÁvgl«gM«ö#k V.Í >« \ X í-i V V > d v. 0\|\ I|),(ÍK ip \|1® AH \ J\ akpak diköPp^Äk. 1 As. L igénypont smiati íiiíKísií done? fclksssnáMsa-a «IjárMsap ahogy a? I v ρνρο,χχ,Α. bás'íhéiylkéhés ifefcyiiys vas, íihek CD R'évk egyAe axis min· H; E\R\ R\ R^és R' 8É$:'bái&amp;: ha R‘ ksg£' R; egyik;.' haló <·; a/ R ' vagy R < amely sem is;ks, H és Ki* v agy R'· sgyAe bab és az R' vagy Ry amely 'x4 hv»k, *ï ' , xa' î a l'aä<v>a,xv h'iKKvS ï xRl. R e».R·' H-ea R'esl·- sgvske H. sa R' vaavRv asseiy iSv'ii; H. n\á ' xrJal aiius vagy aiiok >iv ha E.· <;s R<! M is Rí és R; al.kll.; 1' o:»ás ο:α::;Ι alkii: vagy ;àï R' hak\ Rk*k;«iÈ'îsl pxlsvkxsíbl bük .wkiäfk ^ μ v.'vsabsva VS;;' vagy v.ük·. vagy (si R' bab. ükikaykbmi. psrhaisaikíi, alkîl, aaaeîyîvyk van 1 -4. jiaésva-onga, tssrn vagy ssano:. és kM| R'N vs R? Maik legalább b&amp;ms ÍR vagy (4|: R' Mio, alkhmolksoi. perk; kalb:, ylldk Mlél yhék y&amp;U I Ά MÉ4lf m|ik ak;x> Vagy class;: as: kR kR R<: <·:; R ' H; vagy (3! R? haky metibkulibîhi, psvhaomsekb gesRUsemuSkm, «pöpás sum vagy cRseïssï vagy lé; R balo. OK-Sikyullbsnl. pérfiyötsÁbgU pcnloonvcibox; impmpk. s sam f ggy oiàkh; aa R. R R R k' <-\ R: köcib legâikbhilâtdm H:; vagy fa) R"' halo, makbíRilivkl, p-víkiom-ckl pcolfeonvcshoxl saopropp. jgim vagy okaio; fs: RR RR r &amp;&amp;' IL P Ab L sgèpÿjKsgl vacaisl; mhyvli daopt RètAaàpsslaam «lisî'tsbssg ab sag y as a a : -4 igéssyp-xsmk bákíssRyiRIkgs deieiidvá vsa, ápíils sIkxskirRöSssr vcgyvïs; k; vas véïamsva s iRsveikvmk kbauh SRkû&amp;lésiR'kikïsul: Rvaæal '.sxulSsaaœâd'i 2··ϊ.·!κ':ν····Ι·flp0g-ik-iyslmsRRévbe! yskUpvaihal; 2,3“Ds Usllaassmlll·:#3:sklm/c- boom! sva!Ibaamkh beam; RKbIRîRâkad.: RJdéik;!^ s?:uiîo sassal: 2^ICI3m4;4ibm'/b-bkkssi: basas! vmifksasbck 2'gRmv4-a?:íh;«rmsVlbiv:-hi;kov; kííasí>|:s:É»lföMsssR 2·.νκ!··Λ::·η;>:!··ο\> be·;.«;! svalRsaapiRh ί%='νΜέΐίτ;<>®4νΐ2:--·0ί^Ιίί£ϊΐ^!%ί^Ι?ζίΐϊ|ϊ.2ΐ>ΐΐί>ί£0Ϊ saulk-sviíísxf. s«itlbsmss.kh 2 ' KilèpbR R:Rk<RSRb:RsRRi 2.4.b-Tsv-:2xsprs>p;l--m-ki'iíX'V· be«·«?! saslthgíysid; 2,4-D:bv:«<mmr'hK!m\i be«;«;! a«3n>;;asnnl; 2 - k lu;>r Λ í; :<1 rs>Xΐ bekáol xmbWsnsx!;
  2. 2- Bnkímkviksiuvs:: beásol sbidhMaßud: 2RlYi!hiomxskl>-V'-;:k:mAS be«;«?: :;««ΗΑ:νο;Αϋ: Rklildfxmi-xS-i'kpR beásol ssáí1«itsss?k;' és r= γϊϊ í;í k gyégvsgasésSsíikg sllogadlyké «RR « Λ a L sgepybgsí ms?;«;«! skmvl! 4mú$ Rkhas/nakkra eljárásban. ahogy agyak !>4, igib-ypo-nsR MsgelyiMbgs dehmásva va·;. afó a vagyaiéi: 2·.led- :V-hsdîi>5d beásol aauHbaaimb, A-Hsdam 2 slrtabeRRdtboi! te»á ssùllbvamàl 2-Pisés?-«-!bdm;d beasét ssulRaásmid, &amp;ÍÜ4$*MMém%i xés;l kíVarní;!, Á^BsBöSÍR-IíSíháJVi beírasd sasdfösaöJkh vagy .2 · í Γ ;i ,t h.i - >ΐ í -xí·: Si ? > · .V · ív ; <1 r ·: v < ;. bas;;: ai s«;!b;a«:b;l ti, Ae I. .aRkypos-s ágémkkáíksíksl dobos: :pdbbs2S«4iáM3 é?|àïàvhks5, ahogy sa ag 1··4, igbpypösdöR Asvsssvlyskvbca definiálva v*r>. also! $ ;b·:«.«! Rwo KépletRR sgérbth vygyüîfiR
    vggg iSîîssk sb§;g -ató m:' m W" Μ; JH,·.JÜt j.ès·· Èfi-tó «· oálasgívg S Mvéfegö kiíKÜl: ill, Mls> ÂfcfêÂïjcjj* |jV iped^ifôàlfâs ®fe>· -am, ;i»t, atkoM, periwktaUcok*, a*k:l. s*ut>\«im*U ani";«, •*feîÂlÎiij^r siyïpïillïaUÿ IsgífeöésklöáilkÍlí sitâlkitefet}· «ÄÄ»xt* v\<^!k u a t t 'v * , » es ολ!- Í h1 i^v - R B* R' T , 1 .yoi é egy;k ;· gsâs 'v» U .N R g g V „ H ^c-.R'b ο^Λ ï, u- ik' e aboi R\ R\ it· F H, F.“ <-s 8* ijjyîtü H', «*, æk R* vagy R\ amsl> j*»o :IÇ.mM stôî» Br feamkls s, y«; hafe&amp;iki vagy «xn; 9· S 1 y s,s > s?.' u' ce R l 's \\ î χ<>λ , 5 S , s^\ fam,el\îRv'5>t»iitefitnah (',.0 Rg-i v: tow* k o-oo? :
    If# ; iíímftr ?aihaastiálá*('a «|Ä«Hdn ptRmoiïàhs h|pe;ionb kezelését«, amely eljáyss a äskU donor hatásos mennyisége a<}»gôîâ%àï e-mldsadji, amelynek err? szüksége vis», aboi a 'tós'o.tii tíonot képei: (1¾ saedaR vegybkS:
    vagy asasak gYÓgvi.garászsiúIvg e!(Rgsäi:igfel:;.&amp;öJ<R altot: Rs H; R4 I-I, be&amp;sií, vagy (esrohiíkopfáiW'iJ; eg K\ R*, R\ Ry da K' fÿggfc'îiemsi ks van választva a következő kd«H; H, O. F, 1 Bt, SO.:CH>, ki* Nik'li 5 ' ,v \> ïVnoI, C\y s'«'U .K5:/ wad, O soopopS, ·! t»tiOta»UO. $«'Rv,o Mh Ί< ,ί. \o' ?“«;ra.:fmis. motioímtí. íV-siviü-piovraiaa». dlmetilami&amp;o, pipertdmo. eiMohssabxi, Oskkipeaidsívibn'áL K-aihzuRamlÍfesií^ÍMk-:Wfeos:Í; kadxvú; észtet. salat««« «;; vKiBiömlastgkig RtUévo. hogy lyíR-,;Ε!, R\ és R legalább egyike saîlionikni«?«. í'L Elkesal fess«' RdhavanáEssn ehsnbbsn gebsoaábs hyp-vixens k-.?.?>:·:sgggy «ijgbb nsmbmnasa vkavo! bo:í?<>? Ibiâses aispáyiségé Magolását aMMMhs kpsMtM vnc ssfesge rab, stol a várasd deres képlet ΠΠ) saMná vegyük?:
    vagy anaM gy<kyaxekkaebkg el&amp;psbható sósa ak>l IV Π: Ib Hí ayáíksl, vagy hc-creelkbl; ff 0: s Q::. Q: :. <y \ ()''’' és a ágy vsa tefimáM, kegy gyám C tisíés: b I; VL* hskg alMIssúlMsk áa|gJn5sibssl!baaísiiiíL gsrhsleäliäi side, ML esasy sdMxg perhMMMM s!M, tsÂMtnèh -Mose aMbsalfsSil, Mdlssslíbái, MbrnMIMM, ssnbsMkMt hattetókks&amp;ikib. di»!k-iiasniia*% IHfly OH, CíCOOkL -C|0->OsiM> MIICM^aMR/EdlEE- €(0}ΝΜ;ρ HHCCPyaikäCC^slllk :β)*ίΐαθΡ» mmWML· O^ikiK'ÇOipàikii NHC(0)áiki], Ç(*M» Öl 4}bif lg ökieatkoxg aiktMlMböl&amp;öMs sf Maliks d, vggÿ yibgulísáü: |s : hak- F, 01, Br, vagy I.
  3. 12. Mlööxll danc-r Mbasahálásía aljârâstes: paimsaâbs· bypMersss késelésére, s«My eljárás asnmii êmm bÉàsps meteyisège. Magolását esalFygsk, éaMyabk erré íMkáéM Fák ahol a aároail dsmox; képötpll) «erim? vegyük r
    vagy annak gyégysaemeebbjj eífegMhSlF MM ebei: Rs Ej R: H, tengik vagy RgsadnçmgànwS-iü; « F: Ff Q!:: (>;:;. Çâk Ö’Mx <M! lággedesé! ki wn vsMshs a MvedreM kebll: C, CHg CH. N. NRb Ô, és S.égy, feggy 0 tkdÖM -msxaMis ρΜΜ, pMal, IMMM, íVrítss, baxel, MeMl, ΜμΜΜΜΜΙ, vagy tiedsaM; KK: E. äikli, sv sL vagy saulknal: vagyíllb I és Hl' haky sRsoMlkiL vagy M&amp;ns vagy (21 b 2 és «MdsgyMJÖ FiggelisníU galy: ÁS halo l\Q: Br. vagy ? il, "Nkmxii á0í« fölkásasáiésís .:4|Msb&amp;ss. fid»8ális kaparnia: k«Âsér«¥ sm«ly pMs Mtslmsm ísFsxxP áo-íat Isa!&amp;»s ísíís^ssip siPpsIâP <î5î?<i-;?Æk. ssesdyssek enc sxkkslgs v;;ss. add &amp; n-kx-s;! slixnor képlsí (II!) s?vn«k vessvxifet:
    vagy sssxssk: gpspBííKrésKsSpg &amp;iS5gadhxéö sekk ahvb IIs H; %* livsssIMk -evy haesx-ckbL >i 0; ,, x \í ' *1 \ " ! \ s V \ ! s \ O. Ix S. ügy hogy Ç llolin, Iéi>:és:»>!, pvxiv>l pood, ùsxkès/oF ksrasi. palsl, hipök Ιοηΐχΐ-ΡΐΡοοχ Vagy kadssvxb; R : ' H, slksls sesi, svgy xmlíésék |s I és: P h?<k>. spxs, aMk vagy ti;p(>.· és isakî F, CL Br. vagy I. ;4. NiítxsyE xim?<rs Féisaxxssásás-xi eprásbsv fHiS-ésísyálss aypspöil ks*<bá;.ére, ssss?<:!> opis? tselssksisasa sísíSXxSsi: pé<sí hadsos !»«sxy;sxyí: adagolásig ssasOvsisL -essdyeek Séds xsükoxgx vkg, shgs 4 aissvxis dosxos,
    15, :Ιό?οχ:; done; hdbaa/mdsis párásba;; ipséöMp hypvnorúa kxvdbsbrc. smejÿ di.vás ktrtsISíkéÍí: SSkíXSXSi ·1ί>'ί:·>ΐ .h:SS:S’>··!>·:'· :':'iC:ï;syÎS::'gi: adagobhwS í : SS : S GXÍV ; k, -S : SSG :. V S · -S k fCS-í XVÚáSOgsS ViSSä, : S< · 5 « í-sísxsxsi chs-XÍS' kíSpk:; : .il) SSsVéssS YVSTVÜieS
    vagy sssíssíik:gyégysxerésxeűRg syiögb#áÍS:&amp; »ója,:Skbk If H: k' H. #;Bkxk vágy ksSsxksxkkl:: xyygs s iàggsîl&amp;sé? syxkx kkè! I ·η;::: Ä; :: :Jíl; ΐΐΙΙΐϊ.Ι. h? g- ·χχ. i k! sa I k i ! xxax : S s Xdgy h;xsroarox;;a:r gyisxs. gmsly í«rííírx=ííixc-îxs sykxb xgységskxa Qk. O'. Q' s| </, asxdysk ôgyüXî áámsísk vék« g ssígsikksslií ;B <ï podcsSkhsss h-xgy gyiM A ·? képsxask; S öxkk>aík£k lidsméikbaMk asexsxxás vsgy heísimsísssíás gyiku. smciy XasKihsasax: gysgii egységsksá Ok Q\ QJ <k· Cg, sradyek sgdd va-xssk ^évc a kseîyskEd xxéya· ikKíiskSkbáxg hogy gyurk B-> kégssséky X r. gr. 0' iák Ok dk í.r és Cg' BgiSütOad ki vus vaOssívs g kkvg|gs:®ik köáSk Ç, 0?!;·.. CH, N. NR:". O és gk kkicví. hogy ha gyüsék Λ és B KsAsHsskspsaask,. s: egéss. Ö-tö! ékg vagy y sgésa a Ό! O kü λ sgéxa O-'éi -x-is; y ögésa (kiél ákg; xxésítsgyik Id és k" fkggsXtekJ k; vas sajkáéivá g kSsdCkégék %Mk Ül, í\ I. Br. SöjC|$y: SOvNHOH. 0F5, éli;.. NO:. Bak. CN. ÜUK OO-k. sb-Uík kOaagxynk éxmsofenkan. prxfaíddshkl. grogé« d-axulík«l mOSMgkg #kastíkp|5éiyg|séx ékaéBkiXékKg g|gsxié|so, dkk-lxsdiox;. <:Β:Ορ«χΟΒχΟΟτ«!.:éési&amp;sglfküi, és Onúsaxdk«:. ·.:< R.^ 11, alldk asil s-sgy sxsxlkxxkk ;é. A i 5 xgégyyosy sgSiksís ««xoxü dsma iéfhépsglâsxa diáié* ha«. ahogy és: g: !>. îygXiypéiXïM» xlellîîMIvà vsxgaköi: à CgfSökB kökké:
HUE10784416A 2009-11-23 2010-11-23 Nitroxil donorok pulmonális hypertonia kezelésére HUE032253T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26369809P 2009-11-23 2009-11-23
US26412909P 2009-11-24 2009-11-24

Publications (1)

Publication Number Publication Date
HUE032253T2 true HUE032253T2 (hu) 2017-09-28

Family

ID=43513876

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10784416A HUE032253T2 (hu) 2009-11-23 2010-11-23 Nitroxil donorok pulmonális hypertonia kezelésére

Country Status (15)

Country Link
US (2) US20110160200A1 (hu)
EP (1) EP2504003B1 (hu)
JP (2) JP2013511556A (hu)
CY (1) CY1118603T1 (hu)
DK (1) DK2504003T3 (hu)
ES (1) ES2611852T3 (hu)
HR (1) HRP20170183T1 (hu)
HU (1) HUE032253T2 (hu)
LT (1) LT2504003T (hu)
PL (1) PL2504003T3 (hu)
PT (1) PT2504003T (hu)
RS (1) RS55697B1 (hu)
SI (1) SI2504003T1 (hu)
SM (2) SMT201700090T1 (hu)
WO (2) WO2011063339A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010328234B2 (en) * 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
CN105130855B (zh) 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
SG10201802862WA (en) * 2013-01-18 2018-05-30 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
EP2925743B1 (en) 2013-05-14 2016-02-03 Active Biotech AB N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
KR20180070672A (ko) 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
EP3490975B1 (en) 2016-07-28 2021-05-05 The Johns Hopkins University O-substituted hydroxamic acids
WO2018128999A1 (en) 2017-01-03 2018-07-12 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219428A (en) * 1961-04-17 1965-11-23 Hooker Chemical Corp O,n-diacylated-3,4-dihalophenylhydroxylamines as herbicides
US3382243A (en) * 1965-05-17 1968-05-07 American Home Prod Acetamides and their preparation
US3948967A (en) * 1968-01-03 1976-04-06 Velsicol Chemical Corporation Aryl urea carbonates
US3661944A (en) * 1970-07-01 1972-05-09 Smith Kline French Lab 4-(n-lower alkanoyl)hydroxylamino-4'-aminodiphenylsulfone compounds
US3746727A (en) * 1971-06-07 1973-07-17 Shell Oil Co Benzenesulfhydroxamic acids and their derivatives
US3751255A (en) * 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) * 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4405357A (en) * 1980-06-02 1983-09-20 Fmc Corporation Herbicidal 3-isoxazolidinones and hydroxamic acids
US4539321A (en) * 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) * 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5721365A (en) * 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
CA2118795A1 (en) * 1991-09-20 1993-04-01 John Crosby Pyranones
WO1993007114A1 (en) * 1991-09-24 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5278192A (en) * 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6200558B1 (en) * 1993-09-14 2001-03-13 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
EP1369409B1 (en) * 1993-06-24 2006-04-05 AMR Technology, Inc. Process for preparing compounds useful as intermediates
JPH09508097A (ja) * 1993-11-02 1997-08-19 アメリカ合衆国 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用
US5700830A (en) * 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
DE19545878A1 (de) * 1995-12-08 1997-06-12 Basf Ag Pyridylcarbamate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5958427A (en) * 1996-11-08 1999-09-28 Salzman; Andrew L. Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
AU741180B2 (en) * 1997-10-24 2001-11-22 Shionogi & Co., Ltd. Antirheumatic
US6596705B1 (en) * 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) * 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
US6297260B1 (en) * 1998-10-30 2001-10-02 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US7045152B2 (en) * 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US20010053795A1 (en) * 2000-06-20 2001-12-20 Bond Richard A. Paradoxical pharmacology
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
DE60122939T2 (de) * 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
WO2003006427A1 (en) * 2001-07-12 2003-01-23 Johns Hopkins University Compounds that release nitric oxide at controlled rates upon photolysis
FR2832634A1 (fr) * 2001-11-29 2003-05-30 Univ Pasteur Utilisation des isomeres l de derives aminoacides de l'hydroxyguanidine pour la production de no, compositions pharmaceutiques les contenant et utilisations pharmaceutiques
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US20040077691A1 (en) * 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050009789A1 (en) * 2003-05-13 2005-01-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service Cyclooxygenase inhibition with nitroxyl
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
EP1846439A2 (en) * 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US20090298795A1 (en) * 2005-06-23 2009-12-03 The Johns Hopins University Thiol-Sensitive Positive Inotropes
WO2007045962A2 (en) * 2005-10-18 2007-04-26 Orchid Research Laboratories Limited Novel hdac inhibitors
US8030356B2 (en) * 2006-03-17 2011-10-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
CN104119310B (zh) 2007-09-26 2017-04-12 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物
EP3067352A3 (en) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
AU2010328234B2 (en) * 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
CN105130855B (zh) * 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途

Also Published As

Publication number Publication date
US20110160200A1 (en) 2011-06-30
EP2504003B1 (en) 2016-11-09
EP2504003A1 (en) 2012-10-03
SMT201700090B (it) 2017-03-08
US20160081951A1 (en) 2016-03-24
HRP20170183T1 (hr) 2017-03-24
PL2504003T3 (pl) 2017-04-28
CY1118603T1 (el) 2017-07-12
ES2611852T3 (es) 2017-05-10
JP2013511556A (ja) 2013-04-04
WO2011063339A1 (en) 2011-05-26
JP2016128481A (ja) 2016-07-14
DK2504003T3 (en) 2017-02-20
WO2011063400A1 (en) 2011-05-26
RS55697B1 (sr) 2017-07-31
SI2504003T1 (sl) 2017-01-31
LT2504003T (lt) 2017-01-25
SMT201700090T1 (it) 2017-03-08
PT2504003T (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
HUE032253T2 (hu) Nitroxil donorok pulmonális hypertonia kezelésére
ES2660317T3 (es) Combinación de fármacos
DE69608096T2 (de) 3,4-diarryl substituierte pyridine zur behandlung von entzündungen
US10239854B2 (en) Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
DK2945620T3 (en) NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX
AU2021269398A1 (en) Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behaviour disorder
JP2014037426A5 (hu)
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JOP20210329A1 (ar) مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز
JP2008502614A5 (hu)
JP2024507414A (ja) ウイルス感染症治療のためのｒｏｃｋ２阻害剤
JPS58159489A (ja) ２，３−ジアリ−ル−５−ハロチオフエン化合物
JP6820015B2 (ja) 効率的ｈｎｏドナーとしての炭素系脱離基を有するｎ−置換ヒドロキサム酸およびその使用
KR100555824B1 (ko) Ｃｏｐｄ의 치료법
JP2018520145A5 (hu)
JP2008520611A5 (hu)
JPH01104013A (ja) 心不全予防治療剤
CN108774220B (zh) 用于治疗心肌缺血的化合物及其应用
JPWO2020158890A5 (hu)
JP2025525058A (ja) ウイルス感染の処置のためのｒｏｃｋ２阻害剤
CN101242831A (zh) 类风湿性关节炎的预防和/或治疗方法
RU2024129974A (ru) Композиция для профилактики или лечения легочного фиброза,содержащая тауродезоксихолевую кислоту или ее фармацевтически приемлемую соль в качестве активного ингредиента
HK40001419B (en) Pharmaceutical compositions comprising nitroxyl donors
CZ20002530A3 (cs) Farmaceutický prostředek, způsob profylaxe, použití pro výrobu léčiva, způsob jeho výroby a léčivo
JP2007001899A (ja) 亜鉛錯体による抗糖尿病薬剤